Keyphrases
Relapsed or Refractory
100%
Peripheral T-cell Lymphoma
100%
Belinostat
100%
Histone Deacetylase Inhibitor (HDACi)
60%
Clinical Trials
20%
Vorinostat
20%
Current Treatment
20%
T-cell Lymphoma
20%
Heavily Pretreated Patients
20%
Clinical Activity
20%
Pharmacology
20%
Romidepsin
20%
Medicine and Dentistry
Peripheral T-Cell Lymphoma
100%
Belinostat
100%
Histone Deacetylase Inhibitor
60%
Clinical Trial
20%
Cancer
20%
Vorinostat
20%
T-Cell Lymphoma
20%
Romidepsin
20%
Chemotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Peripheral T Cell Lymphoma
100%
Belinostat
100%
Histone Deacetylase Inhibitor
60%
Clinical Trial
20%
T Cell Lymphoma
20%
Vorinostat
20%
Romidepsin
20%